Brazil's leading pharmaceutical manufacturer with generics and biotech innovation
EMS is the dominant player in Brazil's pharmaceutical market, operating four manufacturing facilities across the country and maintaining a tech stack anchored in enterprise pharma tools (Veeva, IQVIA, SAP, LIMS). The hiring acceleration—10 roles in the last 30 days—skews heavily toward sales (five positions) and research (two), reflecting a scaling strategy around market penetration and portfolio innovation rather than platform infrastructure.
EMS manufactures and distributes pharmaceuticals across prescription, generic, OTC, and hospital segments in Brazil, operating four production facilities in Hortolandia, Manaus, Brasilia, and Jaguariuna. The company combines domestic market leadership in generics with an international R&D footprint: a research center in Italy (MonteResearch) and U.S.-based biotech operations (Bionovis for biotechnology; Brace Pharma for disruptive innovation; Vero Biotech). The product portfolio spans nearly all medical specialties, with significant strength in high-complexity generics and emerging biotech medicines. The organization maintains regulatory compliance, supply-chain efficiency, and market access as core operational priorities.
EMS holds the #1 position in the Brazilian pharmaceutical market (19 consecutive years) and leads the generics segment since 2013. The company is also among the largest by prescriber preference.
EMS operates Veeva (pharma-specific CRM/compliance), IQVIA (market intelligence), SAP (enterprise resource planning), LIMS (laboratory information management), and Power BI (analytics), plus standard Microsoft Office and GCP.
Other companies in the same industry, closest in size